Detalhe da pesquisa
1.
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Circulation
; 139(14): 1661-1670, 2019 04 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30630341
2.
Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study.
Circulation
; 137(23): 2450-2462, 2018 06 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29526833
3.
Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
J Transl Med
; 16(1): 92, 2018 04 11.
Artigo
Inglês
| MEDLINE | ID: mdl-29642909
4.
Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.
Circulation
; 142(15): 1500-1502, 2020 10 13.
Artigo
Inglês
| MEDLINE | ID: mdl-33044856
5.
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) Study.
Thromb Haemost
; 124(3): 263-273, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37224883
6.
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation after Percutaneous Coronary Intervention: The SWAP-AC-2 Study.
JACC Cardiovasc Interv
; 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38597172
7.
Impact of evolocumab on the pharmacodynamic profiles of clopidogrel in patients with atherosclerotic cardiovascular disease: a randomised, double-blind, placebo-controlled study.
EuroIntervention
; 18(15): 1254-1265, 2023 Mar 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36602868
8.
An Unusual Case of Seronegative Cryoglobulinemic Glomerulonephritis with Dominant Organized IgA Deposits Associated with Staphylococcal Infection: Casual or Causal Relationship?
Glomerular Dis
; 3(1): 140-147, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37901697
9.
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
JACC Cardiovasc Interv
; 16(1): 36-46, 2023 01 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36317958
10.
Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study.
JACC Cardiovasc Interv
; 16(20): 2528-2539, 2023 10 23.
Artigo
Inglês
| MEDLINE | ID: mdl-37609698
11.
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thromb Haemost
; 122(8): 1341-1351, 2022 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-34983074
12.
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
Eur Heart J Cardiovasc Pharmacother
; 8(7): 728-737, 2022 Sep 29.
Artigo
Inglês
| MEDLINE | ID: mdl-35353154
13.
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
Eur Heart J Cardiovasc Pharmacother
; 8(5): 452-461, 2022 08 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34114623
14.
Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study.
BMJ Open Diabetes Res Care
; 9(1)2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33637605
15.
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing.
JACC Basic Transl Sci
; 5(5): 419-428, 2020 May.
Artigo
Inglês
| MEDLINE | ID: mdl-32478205
16.
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study.
Thromb Haemost
; 120(1): 83-93, 2020 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-31470444
17.
Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study.
J Am Heart Assoc
; 9(8): e015865, 2020 04 21.
Artigo
Inglês
| MEDLINE | ID: mdl-32306797
18.
Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study.
JACC Basic Transl Sci
; 4(7): 763-775, 2019 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-31998847
19.
Acute myocardial infarction following 5-fluorouracil treatment.
J Geriatr Cardiol
; 20(7): 551-554, 2023 Jul 28.
Artigo
Inglês
| MEDLINE | ID: mdl-37576478
20.
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC Cardiovasc Interv
; 14(21): 2410-2412, 2021 11 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34736741